Drug profile · INN
retifanlimab-dlwr
ZYNYZ
retifanlimab-dlwr (ZYNYZ) is a programmed cell death protein 1 antagonist. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — retifanlimab-dlwr
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 4
- Programs
- 1
- Data quality
- 0.84
Quick answer
retifanlimab-dlwr (ZYNYZ) is a programmed cell death protein 1 antagonist. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Programmed cell death protein 1 antagonist
Primary target: Programmed cell death protein 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12145943
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 12116374
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 11407759
Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted -
US 11136334
Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
granted
Frequently asked questions
What is retifanlimab-dlwr?
retifanlimab-dlwr (ZYNYZ) is a programmed cell death protein 1 antagonist. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for retifanlimab-dlwr?
ZYNYZ is a marketed brand name for retifanlimab-dlwr. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of retifanlimab-dlwr?
retifanlimab-dlwr has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.